Wesley Hayes, MD
Internal Medicine · Oak Ridge, TNNPI 1780603084
Payments from drug & device makers
Across 447 payments — averaging $14.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- GSK$943
- AbbVie$683
- Pfizer$680
- Boehringer Ingelheim$405
- AstraZeneca$354
- plus $2K from 35 others
What the payments were for
- Food & beverage$6,33899%
- Education$931%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 89 | $1,048 |
| GSK | 72 | $943 |
| AbbVie(2 entities) | 47 | $683 |
| Pfizer | 45 | $680 |
| Boehringer Ingelheim | 30 | $405 |
| AstraZeneca | 20 | $354 |
| Abbott | 18 | $292 |
| Novartis | 14 | $211 |
| Sanofi-aventis U.S. LLC | 12 | $192 |
| Amgen | 12 | $185 |
| Xeris Pharmaceuticals, Inc. | 8 | $121 |
| Lilly USA, LLC | 8 | $111 |
| Amarin Pharma, Inc. | 7 | $105 |
| Biohaven Pharmaceuticals, Inc. | 5 | $86 |
| E.r. Squibb & Sons, L.L.C. | 5 | $84 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $76 |
| Inspire Medical Systems, Inc. | 2 | $73 |
| Phathom Pharmaceuticals, Inc. | 4 | $69 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| Astellas Pharma US Inc | 4 | $64 |
| Merck | 4 | $54 |
| Bayer | 3 | $52 |
| Sumitomo Pharma America, Inc. | 3 | $51 |
| Mylan Specialty L.p. | 3 | $42 |
| Genentech USA, Inc. | 2 | $40 |
| Radius Health, Inc. | 2 | $35 |
| Dexcom, Inc. | 2 | $34 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Eisai Inc. | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| Stryker | 1 | $20 |
| Silk Road Medical, Inc. | 1 | $20 |
| Circassia Inc. | 1 | $19 |
| Nevro Corp. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Mannkind Corporation | 1 | $16 |
| Baxter Healthcare | 1 | $16 |
| Dynavax Technologies Corporation | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Welch Allyn | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $12 |
How this compares
$6,431 in reported general payments places this provider in the 85th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 87 | $121,617 |
| OzempicSemaglutide | 97 | $110,151 |
| EliquisApixaban | 81 | $97,033 |
| MounjaroTirzepatide | 52 | $62,803 |
| FarxigaDapagliflozin Propanediol | 27 | $30,056 |
| TrulicityDulaglutide | 22 | $29,730 |
| XareltoRivaroxaban | 20 | $24,040 |
| JanuviaSitagliptin Phosphate | 12 | $17,498 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $15,746 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 62 | $14,047 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $11,716 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $11,185 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $10,637 |
| Colesevelam Hcl | 17 | $7,392 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,284 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $405 | $121,61787 claims |
| Novo NordiskOzempic | $1,048 | $110,15197 claims |
| PfizerEliquis, Abrysvo | $680 | $101,00193 claims |
| Lilly USA, LLCMounjaro, Trulicity | $111 | $92,53474 claims |
| AstraZenecaFarxiga, Symbicort | $354 | $41,77259 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta | $943 | $35,077100 claims |
| MerckJanuvia | $54 | $17,49812 claims |
| AbbVieSynthroid | $683 | $2,22455 claims |
| Sanofi-aventis U.S. LLCLantus | $192 | $2,21521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Oak Ridge
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.